Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Inessa Yu. Toropova"'
Autor:
Olga A. Aleshina, Kristina Zakurdaeva, Anastasia N. Vasileva, Sergey K. Dubov, Vitaly S. Dubov, Vladimir I. Vorobyev, Lev S. Butaev, Alena M. Sukhareva, Lubov V. Gavrilova, Inessa Yu. Toropova, Marina O. Popova, Aleksandr A. Siniaev, Aleksandr D. Kulagin, Kamil D. Kaplanov, Andrei A. Petrenko, Oksana I. Ochirova, Alina Karpova, Ekaterina Yu. Chelysheva, Anna G. Turkina, Margarita A. Gurianova, Liubov S. Al-Radi, Elena A. Gilyazitdinova, Elena K. Egorova, Yulia A. Chabaeva, Sergey M. Kulikov, Yulia V. Sveshnikova, Mikhail A. Kunst, Vasily Shuvaev, Anzhelika F. Rakhmani, Olga L. Panteleeva, Maria E. Grishunina, Olga S. Samoylova, Ekaterina Vorontsova, Daria V. Baryshnikova, Elena N. Parovichnikova
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia.
Autor:
Inessa Yu. Toropova, Tatiana V. Gaponova, Valery G. Savchenko, Andrei Petrenko, M. Popova, Yulia Sveshnikova, Maria Grishunina, Alina Karpova, Kaplanov Kd, Alena Sukhareva, Anastasia N. Vasileva, Lev S. Butaev, Vera V. Troitskaya, Dasha Baryshnikova, Vitaly S. Dubov, Ekaterina Chelysheva, Kristina Zakurdaeva, Vasily Shuvaev, Oksana Ochirova, Julia Chabaeva, Vladimir I. Vorobyev, Sergei Dubov, Lubov Gavrilova, Olga A. Gavrilina, Aleksander A. Siniaev
Publikováno v:
Blood
Background: Research on the impact of COVID-19 on different patient populations has been of great value for the optimization of patient care since the start of the SARS-CoV-2 pandemic. Earlier, we reported the interim analysis of the immediate outcom
Autor:
Sergey Dubov, Valery G. Savchenko, Lev S. Butaev, Hunan Julhakyan, Yulia Sveshnikova, Inessa Yu. Toropova, Oksana Ochirova, Olga A. Gavrilina, E A Gilyazitdinova, Aleksandr A. Siniaev, Vasily Shuvaev, Anastasia N. Vasileva, Lubov Gavrilova, Maria Grishunina, Kristina Zakurdaeva, Mikhail A. Kunst, Marina O. Popova, Vladimir I. Vorobyev, K D Kaplanov, Al'-Radi Ls, Andrei Petrenko, Yulia A. Chabaeva, Daria Baryshnikova, Vitaly S. Dubov
Publikováno v:
Clinical Lymphoma, Myeloma & Leukemia
Background Patients (pts) with lymphoproliferative diseases (LPD) are at high risk of COVID-19 severe and lethal course. Objective To evaluate treatment outcomes and risk factors in pts with LPD and COVID-19 in a real-world setting. Methods CHRONOS19
Autor:
Oksana Ochirova, Olga A. Gavrilina, Aleksandr A. Siniaev, Anastasia N. Vasileva, Yulia Sveshnikova, Sergei Dubov, Yulia A. Chabaeva, Marina O. Popova, Lev S. Butaev, Kaplanov Kd, Anzhelika F. Rakhmani, Inessa Yu. Toropova, Vitaly S. Dubov, Lubov Gavrilova, Mikhail A. Kunst, Alena Sukhareva, Valery G. Savchenko, Andrei Petrenko, Ekaterina Chelysheva, Kristina Zakurdaeva
Publikováno v:
Journal of Clinical Oncology. 39:e18715-e18715
e18715 Background: Pts with hem diseases are at high risk of COVID-19 severe course and mortality. Emerging data on risk factors and outcomes in this patient population is of great value for developing strategies of medical care. Methods: CHRONOS19 i
Autor:
Vera V. Troitskaya, Eugene E. Zvonkov, Vitalii S. Kanin, V A Lapin, Andrey V. Gubkin, Inessa Yu. Toropova, Olga A. Gavrilina, Elena N. Parovichnikova, Valery G. Savchenko, Nelly G. Gabeeva
Publikováno v:
Blood. 128:5386-5386
Background: The number of elderly patients with diffuse large B-cell lymphoma (DLBCL) in our aging society continues to rise. Median of age for patients with diffuse large B-cell lymphoma (DLBCL) is 60. Approximately 50% of older patients with DLBCL
Autor:
Eugene E. Zvonkov, V A Lapin, Andrey V. Gubkin, Valeri G. Savchenko, Vera V. Troitskaya, Larisa A. Kuzmina, Vitalii S. Kanin, Inessa Yu. Toropova, Elena N. Parovichnikova, Nelly G. Gabeeva, Olga A. Gavrilina
Publikováno v:
Blood. 126:2708-2708
Background: Approximately 50% of diffuse large B-cell lymphomas (DLBCL) are defined as high-grade by IPI. They are characterized by aggressive course and poor response to standard chemotherapy (CT): 5-years overall survival (OS) rate of less than 30%